Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. We investigated the predictors of the rate of glomerular filtration rate decline (Delta GFR) and progression to end-stage renal failure (ESRF) in the 353 patients with proteinuric non-diabetic chronic nephropathies [urinary protein excretion rare (U-Prot) greater than or equal to 1 g/24 hr. creatinine clearance 20 to 70 ml/min/1.73 m(2)] enrolled in the Ramipril Efficacy In Nephropathy (REIN) study. Overall the GFR declined linearly by 0.46 +/- 0.05 ml/min/1.73 m(2)/month (mean rate +/- SEM) over a median follow-up of 23 months (range 3 to 61 months), and progression to ESRF was 17.3%. Using multivariate analysis, higher U-Prot and mean arterial pressure (MAP) independently correlated with a faster Delta GFR (P = 0.0001 and P = 0.0002, respectively) and progression to ESRF (P = 0.0001 and P = 0.003, respectively). Mean U-Prot and systolic blood pressure during follow-up were the only time-dependent covariates that significantly correlated with Delta GFR (P = 0.005 and P = 0.003, respectively) and ESRF (P = 0.006 and P = 0.0001, respectively). After stratification for baseline U-Prot, patients in the lowest tertile (U-Prot < 1.9 g/24 hr) had the slowest Delta GFR (0.16 +/- 0.07 ml/min/1.73 m(2)/month) and progression to ESRF (4.3%) as compared with patients in the middle tertile (U-Prot 2.0 to 3.6 g/24 hr; Delta GFR. 0.55 +/- 0.09 mi/min/1.73 m(2)/month, P = 0.0002: ESRF, 15.3%, P = 0.0001) and in the highest tertile (U-Prot 3.9 to 18.8 g/24 hr: Delta GFR, 0.70 +/- 0.11 ml/min/1.73 m(2)/month, P = 0.0001; ESRF, 33.5%, P = 0.0001). Both Delta GFR (P = 0.01) and progression to ESRF (P = 0.01) significantly differed even between the middle: and the highest tertiles. On the contrary, stratification in tertiles of baseline MAP failed to segregate subgroups of patients into different risk levels. Patients with the highest proteinuria and blood pressure were those with the fastest progression (Delta GFR. 0.91 +/- 0.23; ESRF 34.7%). Of interest, at each level of baseline MAP, a higher proteinuria was associated with a faster Delta GFR and progression to ESRF. On the other hand, at each level of proteinuria, a faster Delta GFR was associated with MAP only in the highest tertile (> 112 mm Hg) and the risk of ESRF was independent of the MAP. Thus, in chronic nephropathies proteinuria is the best independent predictor of both disease progression and ESRF. Arterial hypertension may contribute to the acceleration of renal injury associated with enhanced traffic of plasma proteins. Antihypertensive drugs that most effectively limit protein traffic at comparable levels of blood pressure are those that most effectively slow disease progression and delay or prevent ESRF in proteinuric chronic nephropathies.